血漿タンパク質治療薬の市場規模、シェア、動向分析レポート：製品別、用途別、地域別、セグメント予測、2023年～2030年

血漿タンパク質治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、血漿タンパク質治療薬の世界市場規模は、2023年から2030年にかけて6.1%のCAGRを記録し、2030年までに451億米ドルに達する見込みです。

この成長は、出血性疾患やその他の希少疾患の有病率の高さ、研究開発投資の増加、神経学やその他の治療適応症における血漿由来製品の使用の増加に起因しています。

血漿由来タンパク質は主に、慢性希少疾患の治療における補充療法として使用されます。これらの薬剤に依存する患者は、生涯を通じて定期的な注射や点滴を必要とします。血漿由来の製品は250種類以上あるが、主要企業は一般的に免疫グロブリン（IG）、アルブミン、血液凝固第VIII因子に売上と収益性を依存しています。

過去10年間、血漿タンパク質治療薬市場は、免疫グロブリンが主要な市場シェアを占め、大きな成長を遂げてきました。血漿由来製剤の需要は、疾病の増加、高齢者人口の増加、新興市場における医薬品へのアクセスの改善などが背景にあります。血漿由来の新しい治療法の承認が、需要をさらに促進すると予想されます。中国やブラジルのような新興国市場は、世界市場の巨人に新たな投資の道を提供します。

血漿タンパク質治療薬市場レポート・ハイライト

• 免疫グロブリンの需要は、原発性免疫不全の流行、新たな適応症での使用、投与の容易さなどにより、引き続き増加すると予想されます。
• 血液凝固第VIII因子製剤市場では、非血漿ベースの遺伝子組換え療法が血漿由来製剤と競合する可能性が高いです。
• 原発性免疫不全症セグメントは2022年に26.5%の最大市場シェアを獲得し、予測期間を通じてCAGR 6.2%と大幅な成長が見込まれています。
• アジア太平洋地域は、2022年に35.7%と最大の市場シェアを占め、ヘルスケア支出の増加、多数の患者の存在、疾病に苦しむ患者と治療を受ける患者の比率の改善、薬剤の低コスト生産、診断技術の向上などを背景に、予測期間を通じて8.6%と最も速いCAGRを示すと予想されます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 血漿タンパク質治療薬市場の変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 血漿タンパク質治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 血漿タンパク質治療薬市場：製品の推定・動向分析

• 血漿タンパク質治療薬市場：重要なポイント
• 血漿タンパク質治療薬市場：動向と市場シェア分析、2022年および2030年
• アルブミン
• 免疫グロブリン
• 血漿由来第VIII因子
• その他

第5章 血漿タンパク質治療薬市場：用途の推定・動向分析

• 血漿タンパク質治療薬市場：重要なポイント
• 血漿タンパク質治療薬市場：動向と市場シェア分析、2022年および2030年
• 血友病
• 原発性免疫不全障害（PID）
• 特発性血小板減少性紫斑病（ITP）
• その他

第6章 血漿タンパク質治療薬市場：地域の推定・動向分析

• 地域別の展望
• 地域別の血漿タンパク質治療薬市場：重要なポイント
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • CSL
  • Grifols, S.A.
  • Takeda
  • Octapharma AG
  • Biotest AG
  • Kedrion S.p.A

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 3 North America plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 4 North America plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 5 U.S. plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 6 U.S. plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 7 Canada plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 8 Canada plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 9 Europe plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 10 Europe plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 11 Europe plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 12 Germany plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 13 Germany plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 14 UK plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 15 UK plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 16 France plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 17 France plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 18 Italy plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 19 Italy plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 20 Spain plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 21 Spain plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 22 Denmark plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 23 Denmark plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 24 Sweden plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 25 Sweden plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 26 Norway plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 27 Norway plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 28 Asia Pacific plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 29 Asia Pacific plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 31 Japan plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 32 Japan plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 33 China plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 34 China plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 35 India plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 36 India plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 37 Australia plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 38 Australia plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 39 Thailand plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 40 Thailand plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 41 South Korea plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 42 South Korea plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 43 Latin America plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 44 Latin America plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 45 Latin America plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 46 Brazil plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 47 Brazil plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 48 Mexico plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 49 Mexico plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 50 Argentina plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 51 Argentina plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 52 Middle East and Africa plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 53 Middle East and Africa plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 54 Middle East and Africa plasma protein therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 55 South Africa plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 56 South Africa plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 59 UAE plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 60 UAE plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 61 Kuwait plasma protein therapeutics market, by product, 2018 - 2030 (USD Million)
• Table 62 Kuwait plasma protein therapeutics market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Plasma protein therapeutics: Market outlook
• Fig. 9 Plasma protein therapeutics: Competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Plasma protein therapeutics market driver impact
• Fig. 15 Plasma protein therapeutics market restraint impact
• Fig. 16 Plasma protein therapeutics market strategic initiatives analysis
• Fig. 17 Plasma protein therapeutics market: Product movement analysis
• Fig. 18 Plasma protein therapeutics market: Product outlook and key takeaways
• Fig. 19 Albumin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Immunoglobulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Factor VIII market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Plasma protein therapeutics market: Application movement analysis
• Fig. 23 Plasma protein therapeutics market: Application outlook and key takeaways
• Fig. 24 Hemophilia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Primary immunodeficiency disorder (PIDD) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Idiopathic thrombocytopenic purpura (ITP) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Global plasma protein therapeutics market: Regional movement analysis
• Fig. 29 Global plasma protein therapeutics market: Regional outlook and key takeaways
• Fig. 30 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Plasma Protein Therapeutics Market Growth & Trends:

The global plasma protein therapeutics market size is expected to reach USD 45.1 billion by 2030, registering a CAGR of 6.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The growth can be attributed to high prevalence of bleeding and other rare disorders, rising investment in R&D, and increasing use of plasma-derived products in neurology and other therapeutic indications.

Plasma-derived proteins are primarily used as replacement therapies to treat chronic, rare diseases. Patients that rely on these medications require regular injections or infusions throughout their lives. While there are more than 250 products derived from plasma, key players generally rely on Immunoglobulin (IG), albumin, and factor VIII to drive sales and profitability.

Over the past decade, the plasma protein therapeutics market has grown lucratively with immunoglobulin capturing the major market share. Demand for plasma derived-products is driven by rising disease prevalence, geriatric population, and improved access to drugs in emerging markets. Approvals of new plasma-derived therapies are anticipated to further fuel the demand. Developing countries such as China and Brazil offer new investment avenues to the global market giants.

Plasma Protein Therapeutics Market Report Highlights:

• Demand for immunoglobulin is expected to continue rising owing to prevalence of primary immunodeficiencies, usage in new indications, and ease of administration
• Non-plasma based recombinant therapies are likely to compete with plasma-derived products in the factor VIII market
• The primary immunodeficiency diseases segment captured the largest market share of 26.5% in 2022 and is expected to exhibit substantial growth with a CAGR of 6.2% through the forecast period
• Asia Pacific accounted for the largest market share of 35.7% in 2022 and is expected to exhibit the fastest CAGR of 8.6% over the forecast period fueled by increasing healthcare expenditure, presence of a large number of patients. improved ratio of patients suffering from disease and patients receiving treatment, low-cost production of drugs, and improvement in diagnostic technology.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product
  • 1.1.2. Application
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Plasma Protein Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Plasma Protein Therapeutics market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Plasma Protein Therapeutics market: Product Estimates & Trend Analysis

• 4.1. Plasma Protein Therapeutics market: Key Takeaways
• 4.2. Plasma Protein Therapeutics market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Albumin
  • 4.3.1. Albumin market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunoglobulin
  • 4.4.1. Immunoglobulin market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Plasma-derived Factor VIII
  • 4.5.1. Plasma-derived factor VIII market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Plasma Protein Therapeutics market: Application Estimates & Trend Analysis

• 5.1. Plasma Protein Therapeutics market: Key Takeaways
• 5.2. Plasma Protein Therapeutics market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Hemophilia
  • 5.3.1. Hemophilia market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Primary Immunodeficiency Disorder (PID)
  • 5.4.1. Primary immunodeficiency disorder (PIDD) market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Idiopathic Thrombocytopenic Purpura (ITP)
  • 5.5.1. Idiopathic thrombocytopenic purpura (ITP) market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Others
  • 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Plasma Protein Therapeutics market: Regional Estimates & Trend Analysis

• 6.1. Regional Outlook
• 6.2. Plasma Protein Therapeutics market by Region: Key Takeaways
• 6.3. North America
  • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.3. France
    • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.6. Denmark
    • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.2. China
    • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.3. India
    • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.5. Thailand
    • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5.6. South Korea
    • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.2. Mexico
    • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Market Participant Categorization
  • 7.2.1. CSL
    • 7.2.1.1. Company overview
    • 7.2.1.2. Financial performance
    • 7.2.1.3. Product benchmarking
    • 7.2.1.4. Strategic initiatives
  • 7.2.2. Grifols, S.A.
    • 7.2.2.1. Company overview
    • 7.2.2.2. Financial performance
    • 7.2.2.3. Product benchmarking
    • 7.2.2.4. Strategic initiatives
  • 7.2.3. Takeda
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Octapharma AG
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. Biotest AG
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. Kedrion S.p.A
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives